肝癌射频消融能有效杀死肿瘤，但如何降低肿瘤的局部及远处复发率是亟待解决的关键问题。前期制备出了通过连续空化效应增强射频疗效的包裹薄荷醇的PLGA低维复合物并阐明其机制，但其仅能增效，不能预防肿瘤复发。因此我们提出假说，制备一种既能增效，又能预防肿瘤复发的低维复合物。本研究拟设计出一种硅基低维复合物HSMNs-R837-RGD，其在射频诱导下释放免疫调节剂咪喹莫特（R837），通过HE、TTC及荧光染色、Western blot、RT-PCR等检测wnt/β-catenin等评估细胞坏死及凋亡情况，分析肿瘤内淋巴细胞亚群比例及数量，揭示其射频增效机制，通过观察未消融侧肿瘤大小变化、分析其内淋巴细胞及免疫抑制性细胞亚群比例及数量，阐明其增强抗肿瘤免疫反应机制。本项目有望开发一种射频响应低维复合物，既能增强射频消融疗效，又能增强抗肿瘤免疫反应，为肝癌射频消融后肿瘤复发治疗提供新思路及理论基础。

Radiofrequency ablation (RFA) can effectively treat liver cancer. However, the problems that need to be solved urgently are how to reduce the local and distant recurrence rates. We found that RFA could be enhanced by PLGA-DLM through continuous cavitation via a special radiofrequency solidoid vaporization process. Althrough RFA can be enhanced, the local and distant recurrences of liver cancer can not be prevented. Accordingly, we will design a low-dimentional material (HSMNs-R837-RGD ) that can release imiquimod（R837）under RFA triggeres. The tumor necrosis and apoptosis will be detected by HE,TTC, fluorescent stainings and Western blot, RT-PCR.The enhanced mechanism of RFA will be revealed through the percentage and quantity of lymphocytes and the necrosis and apoptosis of tumor. The mechanism of antitumor immune response will be detected by the tumor size measurements and lymphocytes and inhibitory immune cells percentage and quantity of the tumor that are not ablated. This project will produce a new low-dimentional material that can enhance RFA and antitumor immune response simultaneously. This will offer a new insight and theoretical basis for the treatment of liver cancer recurrence after RFA .